Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

In November 2021, however, she came up against a case nearly impossible to solve. It all started when Elisha woke up with an ...

Add-on oral antihistamines or montelukast (Singulair) do not add much benefit. In three separate trials, researchers randomized 3398 adolescent and adult patients with moderate-to-severe SAR ...

Emmeka Hawkins experienced itchy skin and bumps for over a year before she was diagnosed with chronic spontaneous urticaria.

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who ...

Use anti-itch medication that you can buy without a prescription, such as an antihistamine or calamine lotion. Prevent dry skin by using a fragrance-free moisturizer several times a day. The pressure ...

With unfortunately no curative therapy for chronic spontaneous urticaria (CSU) available for now, the overall goal is to ...

CSU is typically treated with H1 antihistamines ... have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo ...